Abstract: FR-PO0540
Renoprotective Potential of Micronized Purified Flavonoid Fraction in Diabetic Kidney Disease: ANCOVA Adjusted for ACE Inhibitor/ARB/Finerenone and SGLT2 Inhibitor Use
Session Information
- CKM: Clinical - Trials, Epidemiology, and Biomarkers
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Cardiovascular-Kidney-Metabolic Health
- 602 Cardiovascular-Kidney-Metabolic Health: Clinical
Author
- Choi, Yoobem, Dongsuwon General Hospital, Suwon-si, Gyeonggi-do, Korea (the Republic of)
Background
Diabetic kidney disease (DKD) progresses despite ACEi/ARBs, SGLT2 inhibitors (SGLT2i), and finerenone. Micronized purified flavonoid fraction (MPFF), an oral flavonoid with antioxidant and anti-inflammatory activity, shows experimental renoprotection but limited clinical DKD evidence.
Methods
We retrospectively analyzed 86 DKD patients followed every 3 months for 12 months (2024-2025) with stable glycemic control and no hospitalization or dialysis. Patients on MPFF for >=3 months formed the MPFF group (n=36); those without MPFF or on MPFF for <3 months formed the non-MPFF group (n=50). ANCOVA assessed 12-month changes in eGFR and urine albumin-to-creatinine ratio (uACR; log-transformed) in two models: Model 1 adjusted for baseline value and ACEi/ARB/finerenone use; Model 2 (full) further adjusted for SGLT2i use. MPFF-by-treatment interactions were tested.
Results
Baseline features were balanced, including SGLT2i use (72.2% vs 74.0%, p=1.000); ACEi/ARB/finerenone use was lower in MPFF (27.8% vs 50.0%, p=0.065). MPFF had less eGFR decline (-0.22+/-3.76 vs -3.40+/-3.70 mL/min/1.73m2): Model 1 B 2.73 (95% CI 1.12-4.34), p=0.001; Model 2 B 2.73 (1.13-4.34), p=0.001. MPFF also showed greater uACR reduction (-44.25+/-60.47 vs +51.16+/-118.31 mg/g): Model 1 GMR 0.675 (0.565-0.808); Model 2 GMR 0.677 (0.569-0.804), both p<0.001. Findings persisted after adjusting for age and sex. No MPFF-by-ACEi/ARB/finerenone or MPFF-by-SGLT2i interactions were detected.
Conclusion
MPFF was independently associated with attenuated eGFR decline and reduced albuminuria in DKD, beyond ACEi/ARB/finerenone and SGLT2i, with consistent effects across subgroups. Prospective randomized trials are warranted.
Table 1. Baseline characteristics and 12-month renal outcomes by MPFF use.
Figure 1. Twelve-month renal outcomes and adjusted effects of MPFF in DKD.